Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
- Published in:
- Prostate, 2017, v. 77, n. 11, p. 1179, doi. 10.1002/pros.23369
- By:
- Publication type:
- Article
Works matching IS 02704137 AND DT 2017 AND VI 77 AND IP 11
Results: 7
1
2
Issue Information - Editorial Board.
- Published in:
- Prostate, 2017, v. 77, n. 11, p. 1177, doi. 10.1002/pros.23333
- Publication type:
- Article
3
Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
- Published in:
- Prostate, 2017, v. 77, n. 11, p. 1187, doi. 10.1002/pros.23377
- By:
- Publication type:
- Article
4
Dose considerations for anti-cancer drugs in metastatic prostate cancer.
- Published in:
- Prostate, 2017, v. 77, n. 11, p. 1199, doi. 10.1002/pros.23378
- By:
- Publication type:
- Article
5
A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
- Published in:
- Prostate, 2017, v. 77, n. 11, p. 1213, doi. 10.1002/pros.23380
- By:
- Publication type:
- Article
6
Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
- Published in:
- Prostate, 2017, v. 77, n. 11, p. 1205, doi. 10.1002/pros.23379
- By:
- Publication type:
- Article
7
Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.
- Published in:
- Prostate, 2017, v. 77, n. 11, p. 1221, doi. 10.1002/pros.23382
- By:
- Publication type:
- Article